Latest Prostate cancer Stories
redOrbit Staff & Wire Reports – Your Universe Online Men suffering from prostate cancer are four times more likely to experience erectile dysfunction (ED) than those without the condition – a phenomenon caused largely by the treatment process, according to the UK-based Macmillan Cancer Support charity. According to the Belfast Telegraph, the organization said there are currently about 160,000 men being treated for prostate cancer in the UK who are suffering from ED. As they...
New Findings Emphasize Oncotype DX's Real-life Impact for Patients and Physicians and Reduction in Healthcare Costs, Underscore Value of Broader Access for All Patients REDWOOD CITY, Calif. and ST. GALLEN, Switzerland, March 15, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of results from 22 studies at the 13(th) St. Gallen International Breast Cancer Conference highlighting the impact of the Oncotype DX® breast cancer test around the...
New Products Build on Growing Adoption of SonaCare Medical HIFU Technologies Following a Record 230% Increase in International Sales and a 3X Expansion in International Distributors CHARLOTTE, N.C., March 14, 2013 /PRNewswire/ -- SonaCare Medical, LLC (SonaCare Medical), a leader in minimally invasive high intensity focused ultrasound (HIFU) technologies, will showcase two new HIFU products at the 28(th) annual European Association of Urology (EAU) Congress, in Milan, Italy, March...
CALGARY, March 14, 2013 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC) (NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the year ended December 31, 2012. "We were very pleased to present our first randomized clinical data from our head and neck cancer clinical study in 2012," said Dr. Brad Thompson, President and CEO of Oncolytics. "In addition, in order to support our program, which now includes seven...
Findings suggest value of Oncotype DX in tailoring radiation therapy treatment for select node-positive patients treated with hormonal therapy and chemotherapy REDWOOD CITY, Calif., March 13, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive results of a large study that demonstrates the Oncotype DX® Recurrence Score® result to be a robust predictor of loco-regional recurrence (LRR) in node-positive (N+), estrogen receptor (ER) positive patients...
A study from the Regenstrief Institute and the Indiana University Center for Aging Research has found that many older adults are hesitant to halt cancer screenings even when the screenings may no longer be beneficial or may even be potentially harmful. The study is among the first to explore older adults' perceptions of recommendations to halt screenings for breast, prostate, colon and other cancers as they age. "Older Adults and Forgoing Cancer Screening: 'I think it would be strange'"...
Storm Team 4 Chief Meteorologist Doug Kammerer joins LUNGevity to spread awareness and information about lung cancer WASHINGTON, March 11, 2013 /PRNewswire-USNewswire/ -- For the second year,LUNGevity Foundation, the nation's largest lung cancer-focused nonprofit, will participate in the NBC 4 Health and Fitness Expo March 16 - 17, 2013 from 9 am to 5 pm at the Walter E. Washington Convention Center in Washington, D.C. LUNGevity Foundation will host the "Take a Lap with LUNGevity"...
TUCSON, Ariz., March 8, 2013 /PRNewswire/ -- For millions of patients, personalized healthcare, or fitting the right treatments to patients based on an individual's particular genetic make-up, means the difference between life and death. Our expanding knowledge of disease mechanisms and individual genetic variation, along with advanced testing technologies enables physicians to provide more precise diagnoses and targeted treatments for all patients, especially cancer patients....
Conference call to be held on Thursday, March 7, 2013 at 4:30 p.m. Eastern Time BOTHELL, Wash. and VANCOUVER, British Columbia, March 7, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today highlighted key clinical development activities for its two product candidates, custirsen and OGX-427, and announced its fourth quarter and year end 2012 financial results. Custirsen Clinical Development Highlights The Company announced completion of patient enrollment of...
Men with low-risk prostate cancer who previously had to choose between aggressive treatment, with the potential for significant side effects, and active surveillance, with the risk of disease progression, may have a new option. Focal laser ablation uses precisely targeted heat, delivered through a small insertion and guided into the prostate by magnetic resonance imaging, to burn away cancerous cells in the prostate. A small, phase 1 trial, to published early online in the journal...
